Kamdar, M., Solomon, S., Arnason, J., Johnston, P., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., Izutsu, K., Morschhauser, F., Lunning, M., Ribrag, V., Lin, Y., Bhatnagar, R., Montheard, S., Abramson, J. (2025). Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM. Blood. https://doi.org/10.1182/blood-2025-3710